IMPALA aims to engage with Health Authorities inspectors on defining guiding principles for the use of advanced analytics to complement, enhance and accelerate current QA practices
The IMPALA ecosystem (industry, regulators, patients) will contribute to a change in paradigm for QA, i.e., where co-developed advanced analytics and best practices can help detect and mitigate issues faster, reduce the burden of retrospective, time-consuming traditional QA activities and ultimately accelerate approval and patient access to innovative drugs
Make valuable contributions to shift the quality assurance paradigm in the biopharmaceutical industry
Connect with experts across the industry
Quality Briefs
Audit Site Selection
Anomaly Detection in Clinical Data
AI Powered Regulatory Intelligence
Education
Arpana Patel2024-10-01T10:35:01-04:00October 1, 2024|News, Work Products|
Arpana Patel2024-06-27T16:04:12-04:00June 27, 2024|News|
Arpana Patel2024-06-26T16:09:12-04:00June 26, 2024|News|
Arpana Patel2024-06-24T16:55:12-04:00June 24, 2024|CSR, News|
The IMPALA Consortium provides the strategic focus for working across the Biopharmaceutical ecosystem to develop and gain industry-wide consensus for the adoption of improved QA using advanced analytics and best practices to be used across the industry; ultimately improving patient outcomes and quality care at greater efficiency and greater speed.
Copyright © | IMPALA Consortium. All Rights Reserved.